Celldex Therapeutics inc (CLDX) - News Archive

In a groundbreaking presentation at the AAAAI 2025 conference, Celldex Therapeutics showcased compelling preclinical data for its bispecific antibody program, CDX-622. This innovative therapeutic candidate targets criti...

Celldex Therapeutics Advances Barzolvolimab Research with Promising Results in Atopic Dermatitis and Urticaria HAMPTON, N.J. Dec. 19, 2024 In a significant stride for dermatological therapeutics, Celldex Therapeutics, I...

: Celldex Therapeutics, Inc. has announced the commencement of a Phase 1a clinical trial for CDX-622, a bispecific antibody aimed at addressing chronic inflammatory diseases. This study represents an important step in e...

In a landmark presentation at the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Celldex Therapeutics announced compelling results from its Phase 2 study of Barzolvolimab in patients suffering fro...

Exploring the Promising Efficacy of Barzolvolimab: A Potential Game-Changer in Chronic Inducible Urticaria and Prurigo Nodularis Treatment Options In a noteworthy advancement for the management of chronic skin condition...

Chronic Spontaneous Urticaria (CSU) is a debilitating and chronic skin disorder characterized by the sudden emergence of itchy hives, swelling, and other symptoms that last for six weeks or more. It affects millions of...

Celldex Therapeutics Reports Impressive Phase 2 Study Results for Barzolvolimab in Chronic Urticaria at EAACI 2024 Celldex Therapeutics, Inc. (NASDAQ: CLDX), a leading biopharmaceutical company dedicated to developing d...

Barzolvolimab Shows Promise in Treatment of Prurigo Nodularis and Chronic Spontaneous UrticariaIn a recent announcement, Celldex Therapeutics, Inc. shared positive updates regarding their experimental drug, barzolvolima...

(NEJM) reports on an important development announced by Celldex Therapeutics, Inc., regarding their clinical study of barzolvolimab, an investigational compound intended for the treatment of chronic inducible urticaria...

Celldex Therapeutics Announces Pricing of Upsized Public Offering, Expected to Raise $400.4 MillionCelldex Therapeutics, Inc. (Celldex), a biopharmaceutical company focused on developing targeted immunotherapies for the...

Hampton, N.J., Feb. 28, 2024 - Celldex Therapeutics, Inc. (Nasdaq: CLDX) has recently announced its proposal to offer and sell shares of common stock in an underwritten public offering, with an added option for underwri...

Celldex Therapeutics Presents Positive 12-Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaCelldex Therapeutics, a leading biopharmaceutical company, announced today the promising findings f...

Celldex Therapeutics Announces Proposed Public Offering of Common Stock for Continued Product DevelopmentHAMPTON, N.J., Nov 07, 2023 - Celldex Therapeutics, Inc. (Nasdaq: CLDX), a leading biopharmaceutical company, has...

In an exciting development for patients suffering from Prurigo Nodularis (PN), Celldex Therapeutics recently presented highly encouraging data from their Phase 1b study, indicating a substantial reduction in itch and im...